88139-91-7

Basic information

• Product Name: 2-Hydroxymethyl-5-bromopyridine
• Synonyms: 2-HYDROXYMETHYL-5-BROMOPYRIDINE;(5-BROMOPYRID-2-YL)METHANOL;(5-BROMO-PYRIDIN-2-YL)-METHANOL;5-BROMO-2-HYDROXYMETHYLPYRIDINE;5-Bromo-2-hydroxymethylpyridin;(5-BROMO-PYRIDIN-2-YL)METHANOL (5-BROMO-2-HYDROXYMETHYLPYRIDINE);5-Bromo-2-pyridinemethanol;(5-Bromopyridin-2-yl)methanol ,98%
• CAS NO: 88139-91-7
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• EINECS: 476-710-3
• Product Categories: blocks;Bromides;Pyridines;Pyridine;Building Blocks;Pyridine Series;Heterocycle-Pyridine series
• Mol File: 88139-91-7.mol
• Article Data: 43

Chemical Properties

• Melting Point: 59-60°C
• Boiling Point: 0°C
• Flash Point: 0°C
• Appearance: light yellow cryst.
• Density: 1.669 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.09±0.10(Predicted)
• CAS DataBase Reference: 2-Hydroxymethyl-5-bromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxymethyl-5-bromopyridine(88139-91-7)
• EPA Substance Registry System: 2-Hydroxymethyl-5-bromopyridine(88139-91-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 22-26-36/37/39-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 88139-91-7(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow Cryst

InChI:InChI=1/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2

Upstream product

• 31181-74-5 (5-bromopyridin-2-yl)methyl acetate 
• 624-28-2 2,5-dibromopyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 97483-77-7 2-Cyano-5-bromopyridine 
• 77199-09-8 5-bromo-pyridine-2-carboxylic acid ethyl ester 
• 29682-15-3 methyl 5-bromopicolinate 
• 30766-11-1 5-bromoisonicotinic acid 
• 110-91-8 morpholine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 900186-89-2 C₂HF₃O₂*C₆H₆BrNO 
• 3430-13-5 5-bromo-2-methylpyridine 
• 109-06-8 α-picoline 
• 900186-88-1 trifluoro-acetic acid 5-bromo-pyridin-2-ylmethyl ester 
• 31181-64-3 5-bromo-2-methyl-pyridine-N-oxide 

Downstream Products

• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 936342-91-5 5-bromo-2-chloromethylpyridine monohydrochloride 
• 1078575-71-9 (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)methanol 
• 145218-19-5 5-bromo-2-(bromomethyl)pyridine 
• 1400581-07-8 (3S,4S)-benzyl 3-((3-carbamoyl-6-(6-((1,3-dioxoisoindolin-2-yl)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazin-4-yl)amino)-4-ethylpyrrolidine-1-carboxylate 
• 1400581-09-0 (3S,4S)-benzyl 3-((6-(6-(aminomethyl)pyridin-3-yl)-3-carbamoylpyrrolo[1,2-b]pyridazin-4-yl)amino)-4-ethylpyrrolidine-1-carboxylate 
• 1400581-10-3 (3S,4S)-benzyl 3-((3-carbamoyl-6-(6-((2-methoxyacetamido)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazin-4-yl)amino)-4-ethylpyrrolidine-1-carboxylate 
• 1400579-56-7 4-(((3S,4S)-1-(5-cyanothiazol-2-yl)-4-ethylpyrrolidin-3-yl)amino)-6-(6-((2-methoxyacetamido)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1419605-01-8 N-(diphenylmethylene)-6-(methylsulfonylmethyl)pyridin-3-amine 
• 1419605-05-2 phenyl 6-(methylsulfonylmethyl)pyridin-3-ylcarbamate 
• 1419605-07-4 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(methylsulfonylmethyl)pyridin-3-yl)urea 
• 31795-61-6 6-(hydroxymethyl)pyridine-3-carbonitrile 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS AND USES THEREOF

The invention relates to novel tetrahydroisoquinoline compounds that are selective estrogen receptor downregulators (SERDs). The present invention also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and to the use of the compounds in the treatment of estrogen receptor (ER) mediated or dependent diseases or conditions, for example cancer such as breast cancer.

Derivatives of hexahydrobenzofuranone useful for the treatment of (inter alia) auto-immune or inflammatory disorders

Heterocyclic-substituted compounds of formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein: Z is - (CH2)n-; (a); (b), wherein R 10 is absent; or, (c) wherein R 3 is absent; the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Het is an optionally substituted mono-, bi- or tri-cyclic heteroaromatic group; B is -(CH 2 ) n3 -. wherein n 3 is 0-5, -CH 2 -O-, -CH 2 S-, -CH 2 -NR 6 -, -C(O)NR 6 -. -NR 6 C(O)-, (d), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR 6 - when the double dotted line represents a single bond, or X is H, -OH or -NHR 20 when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C 1 -C 6 alkoxy) when the double dotted line represents a single bond or when the bond is absent, Y is =O, =NOR 17 (H, H). (H, OH), (H, SH), (H, C 1 -C 6 alkoxy) or (H, substituted-amino); R 22 and R 23 are independently -OH, -OC(O)R 30 , OC(O)NR 30 R 31 , or optionally substituted alkyl, alkenyl, alkynyl, heterocycloalkyl, aryl, cycloalkyl, cycloalkenyl, carbonyl, amino, alkoxy, alkenyloxy, alkynyloxy, heterocycloalkyloxy, cycloalkyloxy, or cycloalkenyloxy; or R 22 and R 10 , or R 23 and R 11 , can form a carbocyclic or heterocyclic ring; and the remaining variables are as described in the specification, Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and blinders to cannabinoid receptors.